Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Plavix Retains Top Slot in FY2014 Japan Drug Sales Ranking: Jiho Tally
October 14, 2015
- Toyama Chemical Licenses RA Drug to Turkish Firm
October 14, 2015
- Astellas Gains Worldwide Rights to Next-Gen DNA Vaccines
October 13, 2015
- (PRESS RELEASE) Shionogi to Spin Off Consumer Healthcare Biz Next Year
October 13, 2015
- Eisai’s Thyroid Cancer Drug Lenvima Approved in S. Korea
October 13, 2015
- AZ Begins Japan PI Trial of CTLA-4 Inhibitor for Malignant Mesothelioma
October 9, 2015
- Ethical Drug Sales Surge 9.0% in August: Crecon Report
October 8, 2015
- Meiji Seika Pharma Commences Long-Term Studies of Safinamide
October 8, 2015
- Merck Lauds Nobel Medicine Prize Winners Omura, Campbell
October 7, 2015
- GreenPeptide Files IND in US for Cancer Peptide Vaccine
October 7, 2015
- Anti-Obesity Effect of Rare Sugar D-Psicose Confirmed: Matsutani Chemical Industry
October 7, 2015
- Eisai Offers Indonesia 151 Million Tablets of Elephantiasis Drug for Free
October 6, 2015
- GSK to Seek COPD Indication for Relvar in January-March 2016
October 6, 2015
- Belsomra Most Heavily Pitched Drug in July: Anterio Ranking
October 5, 2015
- Japan OTC Drug Market Logs 1st Rise in 5 Years: Fuji Keizai
October 5, 2015
- Mitsubishi Tanabe Wins Rights to Regeneron’s NGF Antibody in Asia
October 5, 2015
- Otsuka Files Combination Glaucoma Eye Drops in Japan
October 2, 2015
- ASKA Takes Over 2 Anti-Thyroid Drugs from Chugai
October 2, 2015
- Active Promotion of HPV Vaccines Should Be Resumed: GSK
October 1, 2015
- Mitsubishi Tanabe Raises Full-Year Earnings Projection
October 1, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…